Latest post
Arshad Khanani: “Initial data of phase 1 trial of THR-687 point to clinical efficacy”
Arshad Khanani, M.D., M.A. about the clinical phase 1 data of THR-687.
back of the eye diseases, science community,
Positive phase 1 data indicate THR-687 could be an effective therapy for patients with DME
Oxurion kick-started 2020 with positive topline data from phase 1 clinical trial evaluating THR-687 for treatment of DME.